Semaglutide

Semaglutide

Drug monograph · NCLEX study reference
Trade names	Ozempic, Wegovy, Rybelsus
Therapeutic class	Antidiabetic, weight management agent
Pharmacologic class	GLP-1 receptor agonist
Onset / peak / duration	SubQ once weekly; oral once daily; steady effect after titration.
Half-life / level	Half-life about 7 days; no routine level.
Routes	SubQ
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	None; supportive.
Pregnancy / lactation	Discontinue; not recommended.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Semaglutide (brand names Ozempic, Wegovy, Rybelsus) — Antidiabetic, weight management agent; GLP-1 receptor agonist.

Identification

• Therapeutic class: Antidiabetic, weight management agent.
• Pharmacologic class: GLP-1 receptor agonist.

Pharmacology

• Mechanism of action: Mimics GLP-1 to enhance glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and increase satiety.
• Onset / peak / duration: SubQ once weekly; oral once daily; steady effect after titration.
• Half-life / therapeutic level: Half-life about 7 days; no routine level.

Clinical use

• Indications: Type 2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy), cardiovascular risk reduction.
• Usual dose, route, frequency: SubQ 0.25 mg weekly titrated up to 1 to 2 mg; oral 3 to 14 mg daily.
• Maximum dose / adjustments: Titrate slowly to limit GI effects; no major renal dose change but caution with dehydration.

Safety

• Contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2.
• Black box warning: Risk of thyroid C-cell tumors seen in rodents.
• Interactions: Delays gastric emptying (affects absorption of oral drugs), insulin and sulfonylureas (hypoglycemia); oral form must be taken with little water and no other intake.
• Pregnancy / lactation: Discontinue; not recommended.
• High-alert: No.

Adverse effects

• Common side effects: Nausea, vomiting, diarrhea, constipation, decreased appetite.
• Serious effects to report: Pancreatitis, gallbladder disease, severe GI symptoms, thyroid nodule symptoms.
• Antidote / reversal: None; supportive.

Nursing process

• Assessment before administration: Thyroid and pancreatitis history, renal function, weight.
• Interventions during therapy: Titrate slowly; rotate injection sites; counsel on GI effects.
• Monitor: A1c, weight, GI tolerance, renal function with vomiting.
• Evaluation / expected outcome: Glycemic control and weight reduction.

Patient teaching

• Patient teaching: Inject weekly on the same day; eat smaller meals; oral form on an empty stomach with up to 4 ounces of water then wait 30 minutes.
• Notify provider if: Severe abdominal pain, persistent vomiting, neck lump or hoarseness.
• Administration tips: SubQ abdomen, thigh, or upper arm; rotate sites.